Johnson & Johnson (JNJ) Forecast Overview
This forecast focuses on Johnson & Johnson's (JNJ) stock performance outlook for 2026. As a major player in the Healthcare sector, JNJ's future is influenced by factors such as pharmaceutical innovation, healthcare policy changes, and global health trends. This page offers a concise projection based on current market dynamics.
Names rising to the top of the screen
The strongest names remain easy to scan without losing the valuation context behind the ranking.
| # | Ticker | Company | AI Score | Price | Change | Market Cap | P/E |
|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | 89 | $266.59 | +0.09% | $641.9B | 30.8 |
| 2 | EXEL | Exelixis, Inc. | 98 | $56.20 | -2.14% | $14.4B | 17.5 |
| 3 | INCY | Incyte Corporation | 98 | $123.28 | -2.17% | $25.0B | 15.2 |
| 4 | KRYS | Krystal Biotech, Inc. | 98 | $345.55 | -0.73% | $10.2B | 41.8 |
| 5 | HRMY | Harmony Biosciences Holdings, Inc. | 97 | $41.10 | -1.25% | $2.4B | 13.1 |
| 6 | UTHR | United Therapeutics Corporation | 97 | $503.86 | -0.58% | $21.4B | 16.7 |
| 7 | NHC | National HealthCare Corporation | 97 | $224.92 | -1.02% | $2.2B | — |
| 8 | INSP | Inspire Medical Systems, Inc. | 97 | $73.00 | +7.16% | $2.0B | 14.6 |
| 9 | ETON | Eton Pharmaceuticals, Inc. | 97 | $57.15 | -1.26% | $1.6B | 124.5 |
| 10 | ARGX | argenx SE | 97 | $984.04 | -1.82% | $61.2B | 36.0 |
| 11 | LLY | Eli Lilly and Company | 96 | $1122.21 | -0.07% | $1.1T | 37.6 |
| 12 | ATRC | AtriCure, Inc. | 96 | $53.83 | +1.64% | $2.7B | 249.6 |
Where valuation pressure is clustering
Healthcare100%
Shortlist Context
Johnson & Johnson (JNJ) operates within the Healthcare sector, which is subject to constant innovation and regulatory scrutiny. Understanding these dynamics is crucial for assessing the viability of any forecast. These factors alongside the quantitative projections presented may be worth researching.
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
What factors could influence JNJ's stock price in 2026?
Factors include pharmaceutical pipeline success, regulatory approvals, competition from other healthcare companies, and overall market conditions.
How does this forecast account for changes in the Healthcare sector?
The forecast incorporates industry growth projections, potential policy impacts, and emerging trends such as telemedicine and personalized medicine.
What are the key risks to consider when evaluating this JNJ forecast?
Risks include unexpected regulatory changes, unsuccessful clinical trials, product recalls, and shifts in consumer preferences.